Crystal structure of the NAD complex of human deoxyhypusine synthase: an enzyme with a ball-and-chain mechanism for blocking the active site  by Liao, Der-Ing et al.
Crystal structure of the NAD complex of human deoxyhypusine
synthase: an enzyme with a ball-and-chain mechanism for
blocking the active site
Der-Ing Liao1†, Edith C Wolff2, Myung Hee Park2 and David R Davies1*
Background: Eukaryotic initiation factor 5A (elF-5A) contains an unusual
amino acid, hypusine [Nε-(4-aminobutyl-2-hydroxy)lysine]. The first step in the
post-translational formation of hypusine is catalysed by the enzyme
deoxyhypusine synthase (DHS). The modified version of eIF-5A, and DHS, are
required for eukaryotic cell proliferation. Knowledge of the three-dimensional
structure of this key enzyme should permit the design of specific inhibitors that
may be useful as anti-proliferative agents.
Results: The crystal structure of human DHS with bound NAD cofactor has been
determined and refined at 2.2 Å resolution. The enzyme is a tetramer of four
identical subunits arranged with 222 symmetry; each subunit contains a
nucleotide-binding (or Rossmann) fold. The tetramer comprises two tightly
associated dimers and contains four active sites, two in each dimer interface. The
catalytic portion of each active site is located in one subunit while the NAD-binding
site is located in the other. The entrance to the active-site cavity is blocked by a
two-turn α helix, part of a third subunit, to which it is joined by an extended loop.
Conclusions: The active site of DHS is a cavity buried below the surface of the
enzyme at the interface between two subunits. In the conformation observed here,
the substrate-binding site is inaccessible and we propose that the reaction steps
carried out by the enzyme must be accompanied by significant conformational
changes, the least of which would be the displacement of the two-turn α helix. 
Introduction
The precursor eukaryotic initiation factor 5A (eIF-5A)
undergoes an essential post-translational modification at a
specific lysine residue. The modification occurs via a
series of reactions which convert lysine to Nε-(4-amino-
butyl-2-hydroxy)lysine. Deoxyhypusine synthase (DHS)
catalyzes the synthesis of Nε-(4-aminobutyl)lysine (deoxy-
hypusine), the initial step in the conversion pathway (for
reviews see [1,2]). The reaction involves a single lysine
residue, Lys50, in only one protein, making hypusine
biosynthesis one of the most specific protein modification
reactions known to date [3]. This modification is essential
for eukaryotic cell proliferation, although its exact mode
of action is unclear. Inactivation of the two eIF-5A genes
in yeast [4,5], or as shown recently the DHS gene [6,7],
causes loss of viability by arresting cell proliferation. As
the first enzyme in the modification pathway, DHS occu-
pies a critical position, and its inhibition has potential for
control of eukaryotic cell proliferation.
DHS, a single protein, catalyzes a multistep reaction
(Figure 1) involving two substrates, spermidine and the
eIF-5A precursor protein, and a cofactor, nicotinamide
adenine dinucleotide (NAD) [8–10]. DHS is highly
specific for each substrate. The reaction involves an
enzyme–imine intermediate formed between the 4-amino-
butyl moiety from spermidine and the ε-amino group of
Lys329 in the human enzyme [10]. This intermediate is
essential for the overall reaction [10,11]. Upon addition of
the eIF-5A precursor the butylamine moiety from the
enzyme–imine intermediate is transferred to Lys50 of the
eIF-5A precursor and is reduced to form deoxyhypusine.
The NADH formed in the first step of the reaction is used
for the reduction required in the last step (ECW, unpub-
lished data). 
The amino acid sequence of DHS has been deduced from
either cDNA or genomic DNA for human [12], yeast [13],
Neurospora crassa [14] and Methanococcus jannaschii [15],
and partial peptide sequences have been determined for
the enzyme isolated from rat testis [9] and Neurospora [16].
There is significant sequence identity across these diverse
species, especially in certain regions of the enzyme
(overall 58% identity, 72% similarity for human versus
yeast; 50% identity, 71% similarity for human versus
Methanococcus). The native enzyme exists as a tetramer of
four identical subunits of 40 kDa to 43 kDa, depending on
the species [9,12–16]. The number of active sites per
tetramer has not been characterized biochemically, nor has
the stoichiometry of substrate binding.
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In earlier studies a large number of inhibitors structurally
related to spermidine have been tested as probes for the
spermidine-binding site [17]. Analogs of spermidine, for
example closely related diamines such as 1,7-diamino-
heptane (DAH; Ki = 5.6 µM) and its guanyl derivative
1-amino-7-guanidinoheptane (Ki = 0.01 µM) show competi-
tive inhibition with respect to spermidine (Km=7.2 µM).
These compounds cause inhibition of hypusine formation,
and arrest of proliferation in mammalian cells, including a
variety of human cancer cell lines [18]. From a comparison
of the inhibitory potency of these compounds for the
enzyme in vitro, certain predictions were made regarding
the structural features of the spermidine binding site [17]. 
We report here the refined crystal structure of human
recombinant DHS in complex with NAD, crystallized in
the presence of a known inhibitor, DAH. This structure
reveals the nature of the active site and the positioning of
the catalytic residues. However, density observed in the
active site cannot easily be fitted by this inhibitor and may
be the result of product binding.
Results and discussion
Overall structure of the DHS subunit and the assembly of
the tetramer
DHS exists as a tetramer with four identical subunits
related by 222 symmetry. This tetramer contains two pairs
of tightly associated dimers, A1A2 and B1B2 (Figure 2),
with two active sites, located in each dimer interface. Each
active site has contributions from each of the two subunits,
with one providing most of the catalytic residues and the
other providing the binding site for the NAD. 
Each subunit contains a central six-stranded parallel β sheet,
a small antiparallel β sheet and 16 helices (Figures 3a,b).
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Figure 1
Figure 2
Ribbon drawing [38] of the DHS tetramer model with four bound NAD
molecules (shown as orange stick models). The tetramer consists of
two pairs of tightly associated dimers (i.e. dimer A, with A1 in blue and
A2 in magenta; dimer B, with B1 in green and B2 in yellow). Two NAD
molecules are bound in each dimer interface. The four subunits are
related by 222 crystallographic symmetry.
The reaction catalyzed by DHS. In the first
step of the reaction, the NAD-dependent
spermidine dehydrogenation between N4 and
C5 generates NADH and dehydrospermidine.
This step is followed by spermidine cleavage
to yield 1,3-diaminopropane and an
enzyme–imine intermediate [10]. In this
intermediate the butylamine portion of
spermidine is attached to the ε-amino group
of Lys329 in the human enzyme via an imine
linkage. In the final step, the butylamine moiety
is transferred to the ε-amino group of Lys50 in
the eIF-5A precursor protein, and the resulting
eIF-5A–imine is reduced to form
deoxyhypusine [8–10].
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Structure
The overall fold of each subunit closely resembles the
Rossmann dinucleotide binding motif [19] typical of most
dehydrogenases [20], with insertions at three sites (indi-
cated in yellow in Figure 3b). Near the N-terminal end of
each monomer there is an insertion of some 35 residues
which includes two helices, α2 and α3, with helix α3
packed parallel to the C-terminal helix α7. Between β2
and αC2 there is a cluster of helices (helices α4, α6 αB1,
αB2 and αC1) packed on the edge of the parallel sheet on
the opposite side from the N-terminal tail (Figure 3b). A
three-stranded antiparallel β sheet (βa, βb and βc) and a
short helix α5 are inserted between helix α4 and helix α6
of the cluster, located at the C-terminal end of the parallel
sheet. One side of this small subdomain is part of the
dimer interface that contains two active sites. The N-ter-
minal tail is about 73 Å long (residues 9–39) with a two
turn α helix at its end (residues 10–18). 
The two closely interacting monomers form an extensive
interface, with a buried area of 3221 Å2 per monomer. The
interaction of the two dimers to form a tetramer buries an
additional 2599 Å2 per monomer. In addition, the N-termi-
nal tail from one monomer, for example B2 (yellow;
Figure 2), extends across the side of the small subdomain
of monomer A2 to the A1A2 interface where the short
N-terminal end helix blocks the entrance to the active site
in a ball-and-chain arrangement (Figure 4). The inter-
action of residues 9–25 with the other subunits buries an
area of 948 Å2. This interaction could play a major role in
the control of enzyme activity as it is clear that in the form
observed here this N-terminal helix would have to move
in order to permit spermidine to enter the active-site
cavity. A similar movement would be required for the
penetration of the cavity by Lys50 of the eIF-5A precursor
in order for the enzyme to carry out step 3 in Figure 1. In
its present conformation the enzyme would be inactive,
which is consistent with the pH profile of activity where
maximum activity in vitro occurs at pH 9.2 and the activity
at pH 4.5, where the crystallization occurred, is negligible.
The active site cavity
A striking feature of this enzyme is the buried nature of
the active site (Figure 5). The site is accessed from the
surface by a funnel about 16.4 Å long (measured from
Cα17 of the N-terminal helix of B2 to the sidechain OH of
Tyr305 of A1), which constricts to a narrow tunnel at a
Research Article  Deoxyhypusine synthase Liao et al.    25
Figure 3
α1
α2
α3 αA
α4 α5
α6
αB1
αB2
αC1
αC2
αDαE
α7
β1 β2
βa
βc
βb
β3β4β5β6
Structure
(a) (b)
The topology of the DHS monomer. (a) Ribbon drawing [39] of the
monomer of DHS with bound NAD (shown as a black stick model).
The position of Lys329 is indicated as a light green circle. 
(b) Schematic diagram of the secondary structure. DHS contains a
Rossmann fold [19] (shown in green) with insertions (in yellow) at the
N and C termini and between the second β strand and the second α
helix of the Rossmann fold. For a comparison with the secondary
structures of other dehydrogenases see [20,21]. The β sheets that
are part of the Rossmann fold are numbered sequentially from the N-
terminal end (β1, β2, etc.), while those outside the fold are given
lower case letters (βa, βb, βc); the α helices that are part of the
Rossmann fold are indicated by capital letters (αA, βB, etc.) while
those in the insertions are numbered (α1, α2, etc.). The starting and
ending residues for each element are as follows: α1, 11–17; α2,
42–51; α3, 54–73; β1, 97–104; αA, 112–122; β2, 126–131; α4,
133–142; βa, 145–148; α5, 155–161; βb, 163–167; βc, 169–171;
α6, 173–196; αB1, 203–214; αB2, 220–227; β3, 229–234; αC1,
240–250; αC2, 259–273; β4, 275–281; αD, 286–295; β5,
301–308; αE, 321–327; β6, 333–340; α7, 345–367. The dotted
lines indicate disordered residues.
level corresponding to the positions of the nicotinamide
ring of NAD and the sidechain of Lys329, and then opens
up into a long inner chamber. The shape of this active-site
region immediately suggests the manner in which spermi-
dine and the lysine sidechain of the eIF-5A precursor
could interact with the enzyme during catalysis.
The NAD-binding sites run antiparallel to each other on
the closely interacting pairs of subunits, related by the
dyad axis (Figure 2). The adenosine ends of the two NAD
molecules are fairly close to each other at the mid-level of
the interface, with a distance of 2.69 Å between the two
O3′ atoms. The nicotinamide ends of the two NADs,
however, are separated by 22.9 Å at C4N, and the two
Lys329 residues by 27.5 Å at their terminal NH2s. The
entrances to the cavities containing the active sites reside
on the top and bottom of the pair of subunits in Figure 2.
Each NAD molecule forms hydrogen bonds with nine
residues on one monomer (e.g. A1) and three with the
monomer on the other side of the dimer interface (e.g.
A2). In addition, the NAD makes hydrogen bonds with
four tightly bound water molecules (see Figure 6a). The
adenine ring is sandwiched between the two subunits,
where it forms hydrogen bonds to the sidechains of Asp342,
Asn106 of the closely associated monomer and to the main-
chain of Asp313 of the other monomer. The conformations
of the two ribose groups and the pyrophosphate are fixed
by an intricate hydrogen-bonding network consisting of
sidechains of Thr308, Asp238, Thr131 and mainchains of
Ser105, Gly283, Asp238 from the associated monomer,
Figure 5
Stereoview of the dot surface of the active-
site funnel [40]. The two subunits are colored
light and dark green. Residues that are
possibly involved in catalysis (Lys329, His288
and Asp243) are in red. The nicotinamide end
of the NAD is in gold. The exit to the solvent is
at the top of the figure. The dot surface
defines the solvent-accessible cavity in the
interior of the protein.
Figure 4
A ball-and-stick model of the DHS active-site structure. The N-terminal
helix from a third monomer that covers the pocket entrance is in pale
yellow. The orientation and color scheme of this figure are the same as
in Figure 2. For clarity, only the nicotinamide ring and its adjacent
ribose of NAD are shown. The hydrogen bonds between water
molecules and sidechains of the protein residues are indicated by gray
dotted lines; atoms are shown in standard colours. The N-terminal helix
from the third monomer blocks the access to the active site.
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and the sidechain of Ser317 and the mainchains of Ser317,
Asp316 from the other monomer. This network also
involves three bound water molecules and the O3′A of the
adjacent NAD. The amide nitrogen of the nicotinamide is
hydrogen bonded to the sidechain of Ser109 and Glu137 of
one monomer A1 and with two water molecules. One of the
water molecules is associated with a phosphate group of the
NAD. The nicotinamide ring has no interaction with the
monomer across the dimer interface. There is a cavity
~ 5.5–7.0 Å wide and 9.5 Å long in the dimer interface,
which is likely to be the spermidine-binding site. One side
of the cavity contains the nicotinamide ring and the other
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Figure 6
The details of NAD binding. (a) Schematic
diagram of DHS–NAD interactions. Hydrogen
bonds are shown as dashed lines. Most of the
contacting residues come from one monomer
(open boxes). The shaded residues come
from the other closely associated monomer.
(b) An omit 2Fo–Fc map of the NAD molecule
contoured at the 1σ level. The NAD adopts a
conformation that is only partly extended. The
carboxamide group is rotated by about 23°
from the plane of the nicotinamide ring, similar
to that observed in crystals of lithium NAD
[41] and in NAD bound to several
dehydrogenases [20,21].
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side contains several catalytically important residues (see
below). The nicotinamide ring has the syn conformation rel-
ative to its ribose (Figure 6b). The A face of the ring is
exposed to the solvent channel (Figure 5), consistent with
the A stereospecificity previously determined for NAD in
this reaction [8]. This orientation is in contrast to other well
known dehydrogenases [21–23] which also have A speci-
ficity, but where the nicotinamide of the NAD is in the anti
conformation. It should be noted that there are other excep-
tions to this correlation for which a rational explanation has
been proposed [22]. 
As the NAD is tightly bound and completely buried in the
dimer interface, it is likely that it stays in the enzyme for
a complete cycle of reactions. This is consistent with the
presumption that the same NAD molecule is used for
the catalysis of the dehydrogenation, the first step of the
reaction, and the reduction of the eIF-5A–imine intermedi-
ate, the last step of the reaction catalyzed by DHS. The
hydride transfer for the reduction of the eIF-5A–imine inter-
mediate should, therefore, take place near the region that
has been proposed for the dehydrogenation of spermidine.
Model for spermidine binding
We have constructed a model of spermidine bound to the
enzyme in the active-site cavity (Figure 7). The N4 and
C5 of the spermidine are at the level of the Lys329 and
the C4 of the nicotinamide ring of the NAD. The orienta-
tion of these groups enables the transfer of the hydride ion
from C5 of the spermidine to the re face of the nico-
tinamide ring. Lys329 is positioned to attack the C5=N4
bond of dehydrospermidine in the first transimination
reaction, which results in the formation of an enzyme–sub-
strate intermediate, Enz–N=CH(CH2)3NH2 [10]. In this
model a number of surrounding amino acid residues form
contacts with the spermidine and some could participate
in the catalytic reaction. In particular, the conserved
His288 is in the vicinity of the scissile bond and could act
as the general base for the dehydrogenation reaction and
be the proton donor for the subsequent imine transfer
reaction. In the crystal structure, the Nz atom of Lys329 is
only 3.65 Å from the NE2 of the histidine, and in addition,
there is a water molecule that bridges both nitrogen atoms.
The proximity of these two residues also suggests that the
proton of the initial protonated imine, dehydrospermidine,
might come from His288, which could have acquired a
proton during the dehydrogenation reaction. 
The OD2 of the conserved Asp316 is positioned only
4.3 Å from the NE2 of His288 and 4.8 Å from the Nz of
Lys329. This atom may play a role in substrate binding,
catalyzing the proton transfer from His288 to the dehydro-
spermidine and stabilizing a gem–diamine intermediate of
the type proposed by Jencks [24] for the subsequent
imine transfer reactions. The role of these residues in
catalysis has been confirmed by ongoing site-directed
mutagenesis studies (MHP and ECW, unpublished data).
According to this model, the amino group of the butyl-
amine moiety of spermidine is anchored by Glu323 of
one monomer, while NH2 at the propylamine end of
spermidine can hydrogen bond to Asp243 of the other
monomer. Trp327 is positioned to provide a hydrophobic
interaction with the methylene groups of spermidine.
There are some similarities between this model and the
spermidine-binding site determined for a spermidine
transporter, the only other spermidine-binding protein
for which the crystal structure has been determined
[25,26]. In the spermidine transporter protein the termi-
nal amino groups of spermidine are anchored by acidic
residues, while the methylene chain of spermidine is
further fixed by hydrophobic interactions with up to four
tryptophan residues.
Unexplained density in the interior pocket
DAH, a competitive inhibitor of the reaction at the
optimal pH of 9.2, was present at approximately 5mM
concentration in the crystallization solution. It was hoped
that this inhibitor could be localized at the active site and
would help define the mode of spermidine binding.
However, no electron density was observed that could be
interpreted as due to the DAH. Several small peaks of
density in the active-site region can be readily interpreted
as water molecules with one or more strong hydrogen
bonds to the nearby residues (Figure 8). A continuous
patch of electron density was found at the bottom of the
inner pocket. This density has a length of about 6.4 Å,
Figure 7
A proposed model of the spermidine-binding site of the enzyme
showing the residues most likely to be involved. Asp243 and the
principal binding area for NAD are located on the opposite monomer
to that of the other binding residues. The funnel extends beyond the
spermidine-binding area and includes the pocket which contains the
unexplained density (shown here as a gray stippled area; see Figure
8). Potential hydrogen bonds are shown as dotted lines.
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much shorter than the expected 10 Å for the nine atom
DAH. No reasonable model of DAH can be fitted into
this density and the contents of this binding pocket
cannot be resolved directly by examination of this map.
In addition, the density is 7 Å distant from the nicotin-
amide ring of NAD, being too far for hydride transfer
between the substrate and the C4 atom of the nicotin-
amide. It is conceivable that this density represents a
product derived from the 4-aminobutyl moiety of the
enzyme–imine intermediate at Lys329, either in a cyclized
form (1-pyrroline) [8] or as a straight-chain derivative,
although these molecules do not provide a totally satis-
factory fit to the observed density. The pocket could,
however, conceivably be the binding site of the 4-amino-
butyl moiety of the enzyme–imine intermediate at Lys329
during the reaction.
Possible eIF-5A precursor binding site
We have insufficient information here to propose specific
roles for the active-site residues involved in the reaction
between DHS and Lys50 of the eIF-5A precursor. The
lysine residue from the eIF-5A precursor, however, must
approach the Lys329–imine via the solvent channel seen
in this structure. In the vicinity of the entrance to the
active site there is a small hydrophobic patch, which in the
structure reported here is covered by the small N-terminal
helix originating from the other pair of dimers (see Figure
4). In order for either spermidine or the eIF-5A precursor
to approach the active site, a conformational change must
be induced such that the helix moves away to expose the
active site to the substrates. The large area of the interface
between the two subunits make it seem likely that the
active-site channel will remain in more or less the same
configuration. The presence of the hydrophobic patch at
the entrance to the active site also suggests that hydro-
phobic interactions play an important role in the mecha-
nism of protein–protein recognition between DHS and
the eIF-5A precursor. 
It is intriguing to speculate what controls access to the
active site of DHS. A similar steric block of the active
site of yeast glycogen phosphorylase by a long N-termi-
nal arm is relieved by phosphorylation of a specific threo-
nine residue [27]. In this case the phosphorylation may
trigger a localized protein refolding that alters the dimer
interface and results in activation. For DHS, however,
there is no specific activating event that we are aware of,
and the pH of the crystallization solution may have con-
tributed to this inactive conformation and to the lack of
binding of DAH. The presence of the precursor protein
could induce a conformational change that would facili-
tate the reaction, but it cannot be essential as spermidine
dehydrogenation and cleavage can be observed in its
absence, albeit at a much slower rate than the complete
reaction. Manipulation of the specific conditions of crys-
tallization may afford insight into the enigma of the
active conformation of DHS. 
Biological implications
Deoxyhypusine synthase (DHS) catalyses the first step
in the post-translational conversion of lysine to hypu-
sine and in doing so plays a pivotal role in eukaryotic
cell proliferation. The correlation of hypusine synthesis
(which occurs only in the eukaryotic initiation factor,
eIF-5A) and cell proliferation was first shown in
human lymphocytes and other mammalian cells, but
has also been demonstrated in cells depleted of spermi-
dine (one of the substrates of DHS) by exposure to
inhibitors of spermidine biosynthesis. In fact, an inter-
esting corollary of this observation is the recognition
that an important function of spermidine in supporting
cell proliferation is its role as donor of the butylamine
moiety of deoxyhypusine and hypusine [1,2]. The most
convincing evidence for the vital role of mature eIF-5A,
containing hypusine, derives from gene inactivation
studies in the yeast Saccharomyces cerevisiae. Unless
either one of the two eIF-5A genes is expressed, the
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Figure 8
Stereoview of the unexplained density in the
interior pocket of the active site. Fo–Fc map
contoured at the 4 standard deviation level.
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cells are not viable. Furthermore, disruption of the
single gene for DHS, or inactivation of DHS activity
also causes loss of cell viability. As both eIF-5A and
DHS are highly conserved, and eIF-5A from different
species is functionally interchangeable, it is reasonable
to assume that eIF-5A performs a similar, fundamen-
tal function in cells throughout the eukaryotic kingdom,
and that the presence of hypusine is equally critical for
this function.
In spite of the clear evidence that eIF-5A is essential, its
true cellular function has remained a mystery. Never-
theless, several roles have been postulated for this
protein ([1,2] and references therein). As eIF-5A was
initially isolated from ribosomes of rabbit reticulocyte
lysates and showed activity in stimulating methionyl-
puromycin synthesis (an in vitro assay for the first
peptide bond formation), it was classified as a transla-
tion initiation factor [28]. A more recent eIF-5A deple-
tion study, however, in which overall protein synthesis
was only partially diminished, argues against a role for
eIF-5A as a general protein synthesis factor [29].
Instead eIF-5A may promote the translation of a subset
of mRNAs. In this regard, it is especially interesting
that eIF-5A has been implicated as a cellular factor
essential for Rev function in human immunodeficiency
virus 1 (HIV-1) replication [30], and likewise for Rex
function in human T cell leukemia virus (HTLV) repli-
cation [31]. Rev is presumed to be involved in the
nuclear export of unspliced or partially spliced viral
mRNAs that contain the Rev response element (RRE).
It has been reported that certain dominant negative
mutants of eIF-5A form a complex with Rev and
RRE-containing RNA and inhibit HIV-1 replication in
a human lymphocyte cell line [32]. It is possible, there-
fore, that a function of eIF-5A in normal cells is to
facilitate the nuclear export and/or translation of
certain specific mRNAs. Other lines of experiments
suggest that eIF-5A may be involved in cell-cycle pro-
gression [1,2] (MHP, unpublished data).
Whatever the physiological function(s) of eIF-5A, all
experiments have indicated that hypusine is an indis-
pensable component of eIF-5A activity. Thus the
enzymes that catalyse the formation of hypusine, DHS
and deoxyhypusine hydroxylase, present unique targets
for the manipulation of eIF-5A levels, and thereby of
cell proliferation, through control of one specific reac-
tion. The structure of the active site, as revealed in this
study, helps to define the very strict specificity for the
substrate spermidine, and structurally related inhibitors.
This new information also lays the groundwork for the
design of even more specific and effective inhibitors of
DHS than those developed to date, inhibitors potentially
useful in the therapy of hyperproliferative diseases or in
the control of HIV-1 virus replication.
Materials and methods
Crystallization
Recombinant human DHS was overexpressed and purified as previously
described [10,12], with additional steps of purification, involving succes-
sively, a hydroxyl apatite and butyl sepharose column. Single crystals
of DHS were obtained at room temperature (~20°C) by vapor diffu-
sion in hanging drops. The protein solution was prepared by mixing
50.0 µl of protein at 9.0 mg/ml, 3.0 µl of 0.1 M NAD and 3.0 µl of 0.1 M
1,7-diaminoheptane. The crystallization drops initially consisted of 1.0 µl
of the protein solution and 1.0 µl of reservoir solution (1.7 M sodium/
potassium phosphate and 100 mM HEPES, pH 7.0) resulting in a final
pH of approximately 4.5. The drops were equilibrated against 1.0 ml of
reservoir solutions and crystals were observed to grow to dimensions
0.15 × 0.15 × 0.4 mm in 4–7 days. The crystals were transferred to a sta-
bilizing solution containing 1.8 M sodium/potassium phosphate, 5 mM
NAD, 5 mM 1,7-diaminoheptane, 100 mM HEPES (pH 7.5) and equili-
brated for at least 8.0 h before being used for data collection and
heavy-atom soaking experiments. The crystals are tetragonal, with space
group P4212, unit cell dimensions a = b = 108.3 Å, c = 69.5 Å, with one
DHS monomer per asymmetric unit of the crystal, and a solvent content
of 50% by volume. The crystals diffract to 2.2 Å resolution. 
Structure determination
The structure was determined at 3.0 Å resolution by the single isomor-
phous replacement/anomalous (SIR/AS) difference method [33]. The
X-ray diffraction data were collected at 95K on an RAXIS-II imaging
plate system with CuKα X-rays from a Rigaku rotating-anode generator.
Prior to data collection, both native and heavy-atom derivatized crystals
were washed briefly in a solution containing 1.8 M sodium/potassium
phosphate, 100 mM HEPES (pH 7.5) and 20% glycerol. The crystals
were then mounted on nylon loops with a diameter of 0.1–0.3 mm and
directly frozen in the 95K cold stream generated by an Oxford cryo-
system. Diffraction data were collected at this temperature and were
processed with the program DENZO [34]. The data statistics of the
native data set and the mercury derivative data used for phase determi-
nation are listed in Table 1. The computer protein package PHASES
[33] was used for heavy atom parameter refinement and SIR/AS differ-
ence phase calculation and solvent flattening. Only the centric reflec-
tions were used for the refinement of the heavy-atom parameters of the
mercury derivative. The SIR phases derived from these parameters
were then combined with the phase set generated by the anomalous
difference of the same derivative. This generated a phase set with a
mean figure of merit of 0.659. The final statistics of the crystallographic
phase determination are summarized in Table 1. The 3.0 Å electron-
density map calculated with these SIR/AS phases showed very clearly
the solvent boundary and the secondary structure of the protein as well
as some sidechain features. The connectivity of the map greatly
improved after eight cycles of solvent flattening, assuming 45% solvent
content, enabling the tracing of the polypeptide chain and sequence
assignment. Electron density for the cofactor NAD could be clearly
seen, but there was no clear density for the inhibitor. Neither NAD nor
DAH were included in this initial model. Map interpretation and model
building were effected using the program O [35]. The initial model con-
tained 338 out of 369 residues. 
Refinement
The initial structure was refined with X-PLOR [36], using 90% of the
data between 6.0 and 2.2 Å for which F > 2σ |F|. A free R factor was
calculated for the remaining 10% of the data at each refinement cycle
to avoid over-fitting the data [37]. A total of seven cycles of refinement
were carried out. Each cycle consists of simulated annealing using the
slow-cooling protocol of X-PLOR, restrained individual B-factor refine-
ment and manual model adjustment using the program O [35]. The
NAD molecule was added to the model at the second cycle and six
more residues at the C-terminal end of the molecule were included in
the model at the fourth cycle of the refinement. Water molecules were
incorporated into the model at cycles 2–7 by inspecting the Fo–Fc map
contoured at 3σ after each cycle of the refinement. 
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Two regions of density in the 2Fo–Fc map could be identified in a
pocket near the NAD molecules: one appears to be long enough for a
five-atom single chain molecule such as 1,3-diaminopropane (DAP);
the other is smaller and flattened and connects to the hydroxyl group
of the sidechain of Tyr305. In an Fo–Fc difference map, these two
regions join to form one continuous patch of density (Figure 8). We
have attempted to fit a DAH model into these two pieces of density
causing the free R factor to decrease by 0.4% and the working R
factor by 0.2%. However, the model still seems to be too large for the
density. Alternatively, fitting the larger piece of density with a diamino-
propane molecule and the small piece with a water molecule also
lowered the free and working R factors by the same values. Residual
density still remained, however, between the two pieces in the differ-
ence Fourier map and the shape of the small piece of density does not
look like a water molecule. In addition, measurement by mass spec-
trometry showed no low molecular weight impurity in the DAH sample
used for crystallization. We have therefore concluded that the present
data do not permit the unambiguous assignment of the contents of the
binding pocket.
There are two segments of the protein that appear to be too disordered
to provide adequate electron density: the N-terminal eight residues of
the protein, for which there is no interpretable density; and the region
between residue 75 and 93 where the quality of the density is not suf-
ficient for map interpretation. Also left uninterpreted were the two
regions of density in the active-site pocket. The final model consists of
343 residues, 267 water molecules and one NAD molecule. The
working R factor for this model is 15.3% and the free R factor is 24.2%
for the 16,140 reflections used for the refinement. The rms deviations
from ideal values for bond lengths and bond angles are 0.009 Å and
1.492. The average rms difference in B values is 1.44 Å2 for 344 main-
chain residues and 3.03 Å2 for 287 sidechain residues. The mainchain
tracing of the entire monomer is shown in Figure 9. The final 2Fo–Fc
map of a region of the β sheet is included in the supplementary material
available with the internet version of this paper.
Modeling of the DHS–spermidine complex
We have attempted to model a spermidine molecule within the active
site of the enzyme based on two criteria: first, the C5 atom of the sper-
midine was located within hydrogen-bonding distance of the C4 atom
of the nicotinamide ring of NAD to facilitate hydride transfer; second,
the secondary nitrogen atom N4 of the spermidine should be within
hydrogen-bonding distance of a general base, in this case His288,
for proton transfer. The conformations of the spermidine and some
sidechains of the nearby residues were manually adjusted to avoid
unfavorable contacts, but the sidechain rearrangement was kept to a
minimum. The model for spermidine was created using the program
SYBYL and the manual modeling of the complexes was done using the
computer graphic program O. No additional energy minimization for the
model was performed.
Accession numbers
The atomic coordinates have been deposited in the Brookhaven PDB
with accession number 1DHS.
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Table 1
Crystallographic statistics.
Data set Native DHS DHS-Hg†
Resolution (Å) 2.2 2.7
Number of observations 108 771 57 432
Unique reflections 18 479 11 347
Completeness (%)* 86.1(41.9) 96.1(86.8)
Rmerge (%) 7.4 11.8
*The figures in parentheses represent data for the final shell.
Riso = 12.1%. †Number of binding sites for DHS-Hg = 3. Rcentric = 0.46.
Mean figure of merit = 0.608. Phasing power = 2.79 (single
isomorphous replacement)/1.73 (anomalous). Riso=Σ ||Fh | – |Fn ||, where
Fh and Fn are the heavy-atom and native structure factors, respectively.
Rcentric = Σ ||Fh | – |Fn ||, where the sum is over the centric data.
Figure 9
Stereoview mainchain Cα trace of DHS. Every
tenth residue and the N and C termini are
labeled.
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Supplementary material
Supplementary material available with the internet version of this paper
contains the final 2Fo–Fc map for selected residues of DHS.
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S1Supplementary material
Figure S1
Final 2Fo–Fc map of residues (from left to
right) 276–281 (β4), 103–98 (β1) and
130–126 (β2).
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S2 Supplementary material
Table S2
Interdomain contacts (Å) in NiR-Pa. 
N terminus-A–C domain-B
8A Glu OE2 88B Met N 3.62 WH 
8A Glu OE2 89B Pro N 3.54 WH 
11A Gln CB 50B Cys SG 3.56 VW 
15A Ser N 44B Phe O 3.05 H 
19A Pro O 40B Lys NZ 2.79 H
22A Val O 40B Lys NZ 2.95 H
24A Arg CB 36B Phe CE1 3.60 VW
24A Arg NH2 31B Met O 3.39 WH
N terminus-A–D-domain-B
6A Ala CB 422B Gly CA 3.48 VW 
9A Gln CB 441B Phe CD1 3.69 VW 
10A Tyr CD2 390B Leu CD1 3.43 VW 
10A Tyr OH 327B His ND1 3.50 WH
10A Tyr OH 369B His NE2 2.84 H
14A Ala O 198B Arg NH1 3.01 H
15A Ser OG 223B Glu OE1 2.84 H
16A Ala N 223B Glu OE2 3.09 H
D domain-A–D domain-B
261A Lys O 274B Gln NE2 3.44 WH
263A Ile CG2 269B Met CE 3.66 VW
267A Arg CD 276B Tyr CZ 3.69 VW
274A Gln NE2 261B Lys O 3.20 WH
274A Gln NE2 262B Gln OE1 3.56 WH
276A Tyr CZ 267B Arg CD 3.66 VW
315A Leu O 319B Ser N 2.90 H
316A Thr OG1 318B Thr OG1 2.83 H
316A Thr CG2 316B Thr CG2 3.62 VW
317A Val N 317B Val O 2.93 H
317A Val O 317B Val N 2.88 H
318A Thr OG1 316B Thr OG1 2.74 H
319A Ser N 315B Leu O 2.88 H
319A Ser O 315B Leu N 3.48 H
N terminus-A–C domain-A
28A Ala N 69A Gln NE2 3.25 WH 
C domain-A–D domain-A
48A Ala O 281A Arg NH2 3.28 WH
49A Gly O 281A Arg NH2 2.93 H
53A Val N 279A Glu OE2 3.05 H
54A Leu N 279A Glu OE1 2.74 H
56A Lys O 277A His NE2 2.85 H
VW: van der Waals contacts, H: hydrogen bond, WH: weak hydrogen bond, I: ionic pair. Order is: residue name, type and atom name.
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Table S3
Contacts (Å) of NiR-Pa c and d1 hemes, and phosphate and chloride. 
C heme-A
51A His NE2 601A HEC Fe 2.09
88A Met SD 601A HEC Fe 2.33
63A Leu CD1 601A HEC CHB 3.56 VW
71A Arg NH2 601A HEC O1A 3.01 H 
79A Leu CD2 601A HEC C2A 3.37 VW
84A Thr OG1 601A HEC O1D 2.73 H
89A Pro CD 601A HEC C3C 3.67 VW
8B Glu CA 601A HEC CBC 3.51 VW
D heme-A
182A His NE2 602A HED Fe 2.00
603A HO– O 602A HED Fe 2.05
156A Arg NE 602A HED O1C 2.96 H
185A Arg NH2 602A HED O1A 3.46 WH
198A Arg NH2 602A HED O2B 2.47 H
225A Arg NE 602A HED O2B 2.94 H
225A Arg NE 602A HED OMB 3.12 H
225A Arg NH2 602A HED O2B 3.30 WH
226A Ser OG 602A HED O2A 2.54 WH
245A Tyr OH 602A HED OMB 3.04 H
285A Ile N 602A HED O2A 3.39 WH
372A Arg NE 602A HED O2D 2.80 H
372A Arg NH2 602A HED O1D 3.08 H
425A Phe CE1 602A HED CBD 3.51 VW
483A Gln NE2 602A HED O1D 3.16 H
531A Gly CA 602A HED CMD 3.63 VW
533A Phe CE1 602A HED CGD 3.58 VW
10B Tyr CE1 602A HED CHC 3.34 VW
OH– A
603A HO– O 602A HED Fe 2.05 H
603A HO– O 10B TYR OH 2.61 H
Pi–A
335B His ND1 604A PO4 O3 3.29 H
323W Wat O 604A PO4 O2 3.06 H
540B His ND1 604A PO4 O2 2.81 H
134W Wat O 604A PO4 O2 2.60 H
Cl–A
265A Ser N 605A ION Cl 3.39 H
269B Met N 605A ION Cl 3.28 H
VW: van der Waals contacts, H: hydrogen bond, WH: weak hydrogen bond, I: ionic pair. Order is: residue name, type and atom name.
